甲磺酸阿帕替尼结合脂质体阿霉素在卵巢癌中的应用疗效及对卵巢血流参数的影响

Efficacy of Apatinib Mesylate Combined with Adriamycin Liposome in the Treatment of Ovarian Cancer and Its Effect on Ovarian Blood Flow Parameters

目的:探讨甲磺酸阿帕替尼结合脂质体阿霉素治疗卵巢癌的疗效及对患者卵巢血流参数的影响。方法:选取2016年3月—2018年11月我院收治的复发性卵巢癌患者68例,依据治疗方式不同分为两组,各34例。对照组应用脂质体阿霉素(30 mg/m^2)治疗,研究组应用甲磺酸阿帕替尼(500 mg/d)治疗。比较两组近期疗效、药物不良反应发生情况及治疗前后卵巢血流参数指标水平变化。结果:研究组客观缓解率及疾病控制率均高于对照组,差异有统计学意义(P<0.05);研究组高血压及尿蛋白发生率高于对照组,差异有统计学意义(P<0.05);两组胃肠反应、手足综合症、乏力及骨髓抑制方面的不良反应发生率比较,差异无统计学意义(P>0.05);研究组搏动指数(PI)及阻力指数(RI)水平高于对照组,收缩期峰值流速(PSV)低于对照组,差异有统计学意义(P<0.05)。结论:甲磺酸阿帕替尼联合脂质体阿霉素治疗铂类耐药的复发性卵巢癌患者的客观缓解率高,可有效改善患者的卵巢血流参数,降低收缩期峰值流速,提高搏动指数及阻力指数,且安全性高。

Objective:To investigate the efficacy of apatinib mesylate combined with adriamycin liposome in the treatment of ovarian cancer and its effect on ovarian blood flow parameters.Methods:68 patients with recurrent ovarian cancer admitted to our hospital from March 2016 to November 2018 were selected and divided into two groups(a control group and a study group)according to different treatment methods,34 cases each.The patients in the control group were treated with adriamycin liposome(30 mg/m^2),and the patients in the study group were treated with apatinib mesylate(500 mg/d).The short-term efficacy,adverse drug reactions and changes in ovarian blood flow parameters before and after treatment were compared between the two groups.Results:The objective remission rate and disease control rate in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).The incidences of hypertension and proteinuria in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions such as gastrointestinal reactions,hand-foot syndrome,fatigue and bone marrow suppression between the two groups(P>0.05).The levels of pulsation index(PI)and resistance index(RI)in the study group were higher than those in the control group,and the peak systolic velocity(PSV)was lower than that in the control group,with statistically significant differences(P<0.05).Conclusion:Apatinib mesylate combined with adriamycin liposome has a high objective remission rate in the treatment of the patients with platinum-resistant recurrent ovarian cancer,which can effectively improve ovarian blood flow parameters,reduce peak systolic velocity and increase pulsatility index and resistance index,and has high safety.